Promimic
11.60 SEK
+1.75 %
Less than 1K followers
PRO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Promimic
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.7 | 15.6 | 44.0 | 8.8 | 11.3 | 12.9 | 11.5 | 44.4 |
| EBITDA | -0.1 | -0.6 | -4.3 | -2.4 | 0.1 | -0.3 | -0.3 | -2.9 |
| EBIT | -2.3 | 0.1 | -8.3 | -3.7 | -1.3 | -1.2 | -1.5 | -7.7 |
| EBIT-% | -30.4 % | 0.4 % | -18.9 % | -42.0 % | -11.1 % | -9.6 % | -13.2 % | -17.3 % |
| Profit before taxes | -2.4 | 0.6 | -7.1 | -4.1 | -1.3 | -0.8 | -1.3 | -7.6 |
| Net income | -2.4 | -4.1 | -12.6 | -4.5 | -1.5 | -1.2 | -1.6 | -8.8 |